🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Joincare Pharmaceutical Group Industry clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Joincare Pharmaceutical Group Industry as lead sponsor. Synced 26 Sep 2026
4Current trials
3Recruiting now
1Drug in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Joincare Pharmaceutical Group Industry is the lead sponsor of 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Oseltamivir. The most-studied condition is COPD (Chronic Obstructive Pulmonary Disease).

ClinicalTrials.gov trials by status

  • Recruiting375%
  • Active, closed125%

Trials by phase

  • Phase 2250%
  • Phase 3125%
  • Phase 1125%
01

Clinical trials sponsored by Joincare Pharmaceutical Group Industry

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
NCT07357051 · ClinicalTrials.gov ↗ · Respiratory Viral Infection
Phase 3 Recruiting 2025-11 China
Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers
NCT07207291 · ClinicalTrials.gov ↗ · Bacterial Infections, Urinary Tract Infections, Intra-Abdominal Infections
Phase 1 Recruiting 2025-08 China
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD
NCT07351734 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease)
Phase 2 Recruiting 2025-11 China
A Phase 2 Trial of JKN24011 in COPD
NCT07440524 · ClinicalTrials.gov ↗ · COPD (Chronic Obstructive Pulmonary Disease)
Phase 2 Active, closed 2024-08 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Joincare Pharmaceutical Group Industry trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Joincare Pharmaceutical Group Industry trials

6 conditions
COPD (Chronic Obstructive Pulmonary Disease)2Respiratory Viral Infection1Bacterial Infections1Urinary Tract Infections1Intra-Abdominal Infections1Respiratory Tract Infections1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China43

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in COPD (Chronic Obstructive Pulmonary Disease)

SponsorTrials
Haisco Pharmaceutical Group3
Sir Run Run Shaw Hospital2
Generate Biomedicines1
Ganzhou Hemay Pharmaceutical1

Sponsors with the most current trials registered for this condition.

06

Questions about Joincare Pharmaceutical Group Industry trials

How many clinical trials does Joincare Pharmaceutical Group Industry sponsor?

Joincare Pharmaceutical Group Industry is the lead sponsor of 4 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Joincare Pharmaceutical Group Industry trials recruiting?

Yes. 3 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Joincare Pharmaceutical Group Industry testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Oseltamivir (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.